Search | Clinical Trials Finder

Conditions: HIV-1 Infection
Interventions: blood drawing; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Human Immunodeficiency Virus
Interventions: Maraviroc along with an optimized background antiretroviral drug regimen, Optimized background antiretroviral drug regimen without maraviroc; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 145
States / cities: Hobson City, Alabama • Huntsville, Alabama • Bakersfield, California + 87 more

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: No intervention; Observational study; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 13 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • Orlando, Florida • Tampa, Florida + 2 more

Conditions: HIV Disease
Interventions: Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV, Acute HIV Infection
Interventions: Dolutegravir 50 mg, Lamivudine 300 mg, Abacavir 600 mg; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: HIV Infections
Interventions: KP-1461; Drug
Lead sponsor: Koronis Pharmaceuticals.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 9
States / cities: Bradenton, Florida • Miami, Florida • West Palm Beach, Florida + 6 more

Conditions: HIV Infections
Interventions: DTG/3TC FDC, CAR; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 16
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 12 more

Conditions: Mental Health Disorder, Substance Use Disorder, Stigmatization, Implementation Science
Interventions: Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum, You℞ Decision prescribing platform; Behavioral · Device
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Decatur, Georgia • Duluth, Georgia

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more

Conditions: HIV, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Ft. Pierce, Florida • West Palm Beach, Florida • Wilton Manors, Florida + 2 more

Conditions: HIV Infection, Hyperlipidemia
Interventions: Atazanavir, current antiretroviral regimen; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: HIV Infection
Interventions: DOR/ISL, ART; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Ft. Pierce, Florida • Orlando, Florida + 11 more

Conditions: HIV Infection
Interventions: emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 73
States / cities: Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 47 more

Conditions: HIV Infections
Interventions: Maraviroc; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: 3BNC117, 10-1074, Analytical treatment interruption, Placebo; Drug · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Atazanavir, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 4
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois

Conditions: HIV
Interventions: ibalizumab, Optimized Background Regimen; Drug
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 31
States / cities: Long Beach, California • Los Angeles, California • Palm Springs, California + 21 more

Conditions: HIV-1-infection
Interventions: GS-1219, BVY, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: HIV Infections
Interventions: Early Initiation of Highly Active Anti-Retroviral Therapy, Standard Care; Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 24 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 22
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more

Conditions: HIV Infections
Interventions: Emtricitabine, Enfuvirtide, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: HIV Infections
Interventions: Aldesleukin, HAART; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV
Interventions: ibalizumab, Optimized Background Regimen (OBR); Biological · Drug
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 27
States / cities: Long Beach, California • Los Angeles, California • Palm Springs, California + 18 more

Conditions: Human Immunodeficiency Virus Infection
Interventions: lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL); Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 14
States / cities: Phoenix, Arizona • Beverly Hills, California • Atlantis, Florida + 11 more

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: EVG, Background regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee

Search by objective public record fields.

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

Study of KP-1461 for the Treatment of HIV Positive Patients Who Have Failed Multiple HAART Regimens

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

The IMPROV Project: Improving Mental Health and Substance Use Treatment Provision (IMPROV) Among People Living With HIV (Human Immunodeficiency Virus) in Atlanta

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

Safety and Efficacy Study of Switching From Epzicom to Truvada

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

3BNC117 and 10-1074 in HIV-infected Individuals

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

Study of GS-1219 in Participants With HIV-1

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants